floxuridine has been researched along with Cholangiocellular Carcinoma in 14 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Unresectable cholangiocarcinoma is poorly responded to chemotherapy, especially for the case refractory to gemcitabine and cisplatin." | 7.80 | Can thymidine phosphorylase be a predictive marker for gemcitabine and doxifluridine combination chemotherapy in cholangiocarcinoma?: case series. ( Bae, KS; Cho, JM; Choi, HJ; Go, SI; Kang, MH; Kim, DC; Kim, HG; Kim, MJ; Lee, JH; Lee, US; Lee, WS, 2014) |
| "Unresectable cholangiocarcinoma has a poor prognosis and treatment options are limited." | 7.01 | Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study. ( Akhoundova, D; Bachmann, H; Breitenstein, S; Clavien, PA; Knuth, A; Nguyen-Kim, TDL; Pestalozzi, B; Petrowsky, H; Pietge, H; Samaras, P; Sánchez-Velázquez, P; Siebenhüner, A; Winder, T, 2021) |
| "To evaluate clinical outcomes when HAI chemotherapy is combined with systemic chemotherapy in patients with unresectable IHC." | 6.94 | Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. ( Allen, PJ; Balachandran, VP; Boerner, T; Boucher, TM; Cercek, A; Chapman, WC; Chou, JF; D'Angelica, MI; DeMatteo, RP; Diaz, LA; Do, RKG; Drebin, JA; Fields, RC; Gönen, M; Harding, JJ; Hauser, HF; Hawkins, WG; Jarnagin, WR; Kemeny, NE; Kingham, TP; Lim, KH; Lowery, MA; Majella Doyle, MB; Reidy-Lagunes, D; Saltz, L; Sanchez-Vega, F; Schultz, N; Strasberg, SM; Tan, BR; Vachharajani, N; Varghese, AM, 2020) |
| "This study reports the results of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (dex) in patients with unresectable intrahepatic cholangiocarcinoma (ICC) or hepatocellular carcinoma (HCC) and investigates dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) assessment of tumor vascularity as a biomarker of outcome." | 5.14 | Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. ( Blumgart, LH; D'Angelica, M; DeMatteo, R; Fong, Y; Gönen, M; Gultekin, DH; Haviland, D; Jarnagin, WR; Kemeny, N; Schwartz, LH; Shia, J; Tse, A, 2009) |
| "The results suggest that, compared with historical controls, high-dose focal liver irradiation with hepatic artery floxuridine prolongs survival in patients with unresectable chemotherapy-refractory metastatic colorectal cancer and primary hepatobiliary tumors." | 5.11 | Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. ( Ben-Josef, E; Dawson, LA; Ensminger, WD; Knol, J; Lawrence, TS; Normolle, D; Pan, C; Tatro, D; Ten Haken, RK; Walker, S, 2005) |
| "Unresectable cholangiocarcinoma is poorly responded to chemotherapy, especially for the case refractory to gemcitabine and cisplatin." | 3.80 | Can thymidine phosphorylase be a predictive marker for gemcitabine and doxifluridine combination chemotherapy in cholangiocarcinoma?: case series. ( Bae, KS; Cho, JM; Choi, HJ; Go, SI; Kang, MH; Kim, DC; Kim, HG; Kim, MJ; Lee, JH; Lee, US; Lee, WS, 2014) |
| "Unresectable cholangiocarcinoma has a poor prognosis and treatment options are limited." | 3.01 | Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study. ( Akhoundova, D; Bachmann, H; Breitenstein, S; Clavien, PA; Knuth, A; Nguyen-Kim, TDL; Pestalozzi, B; Petrowsky, H; Pietge, H; Samaras, P; Sánchez-Velázquez, P; Siebenhüner, A; Winder, T, 2021) |
| "To evaluate clinical outcomes when HAI chemotherapy is combined with systemic chemotherapy in patients with unresectable IHC." | 2.94 | Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. ( Allen, PJ; Balachandran, VP; Boerner, T; Boucher, TM; Cercek, A; Chapman, WC; Chou, JF; D'Angelica, MI; DeMatteo, RP; Diaz, LA; Do, RKG; Drebin, JA; Fields, RC; Gönen, M; Harding, JJ; Hauser, HF; Hawkins, WG; Jarnagin, WR; Kemeny, NE; Kingham, TP; Lim, KH; Lowery, MA; Majella Doyle, MB; Reidy-Lagunes, D; Saltz, L; Sanchez-Vega, F; Schultz, N; Strasberg, SM; Tan, BR; Vachharajani, N; Varghese, AM, 2020) |
| "Patients with unresectable intrahepatic cholangiocarcinoma (iCCA) have poor survival." | 2.82 | Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis. ( de Jonge, J; de Wilde, RF; El Hassnaoui, M; Franssen, S; Groot Koerkamp, B; Holster, JJ; Homs, MYV; IJzermans, JNM; Mostert, B; Polak, WG, 2022) |
| "For patients with unresectable intrahepatic cholangiocarcinoma (ICC), treatment options are limited and survival is poor." | 2.79 | Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. ( Allen, PJ; D'Angelica, MI; DeMatteo, RP; Do, RK; Fong, Y; Gönen, M; Gultekin, DH; Jarnagin, WR; Kemeny, NE; Klimstra, DS; Konstantinidis, IT; Schwartz, LH, 2014) |
| "Patients with unresectable intrahepatic cholangiocarcinoma (ICC) or hepatocellular carcinoma (HCC) were treated with HAI FUDR/Dex plus IV Bev." | 2.76 | Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? ( Allen, P; D'Angelica, MI; Fong, Y; Gewirtz, AN; Gönen, M; Gultekin, D; Haviland, D; Jarnagin, WR; Kemeny, NE; Schwartz, L; Yopp, A, 2011) |
| "Resection of multifocal intrahepatic cholangiocarcinoma needs to be considered carefully given the complication rate of major liver resection; HAIP floxuridine chemotherapy may be an effective alternative option." | 1.72 | Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma. ( Aldrighetti, L; Alexandrescu, S; Bauer, TW; Buettner, S; Cercek, A; D'Angelica, M; Franssen, S; Gamblin, TC; Jarnagin, WR; Jolissaint, JS; Kemeny, N; Kingham, TP; Koerkamp, BG; Lamelas, J; Maithel, SK; Margonis, GA; Marques, H; Marsh, JW; Pawlik, TM; Poultsides, GA; Pulitano, C; Shen, F; Soares, KC; Tsilimigras, DI; Weiss, MJ, 2022) |
| "In all three studies, the incidence of hyperbilirubinemia and biliary stent placement within 1 year of treatment was increased with the addition of Bev." | 1.40 | Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab. ( Allen, P; Capanu, M; Cercek, A; D'Angelica, M; DeMatteo, RP; Fong, Y; Gewirtz, A; Jarnagin, WR; Kemeny, NE; Patel, D; Power, D, 2014) |
| "A total of 22 patients (11 with hepatocellular carcinoma and 11 with cholangiocarcinoma) were treated." | 1.30 | Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers. ( Andrews, JC; Ensminger, WD; Kessler, ML; Lawrence, TS; Robertson, JM; Walker, S, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 6 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Holster, JJ | 1 |
| El Hassnaoui, M | 1 |
| Franssen, S | 2 |
| IJzermans, JNM | 1 |
| de Jonge, J | 1 |
| Mostert, B | 1 |
| Polak, WG | 1 |
| de Wilde, RF | 1 |
| Homs, MYV | 1 |
| Groot Koerkamp, B | 2 |
| Soares, KC | 1 |
| Jolissaint, JS | 1 |
| Tsilimigras, DI | 1 |
| Buettner, S | 1 |
| Alexandrescu, S | 1 |
| Marques, H | 1 |
| Lamelas, J | 1 |
| Aldrighetti, L | 1 |
| Gamblin, TC | 1 |
| Maithel, SK | 1 |
| Pulitano, C | 1 |
| Margonis, GA | 1 |
| Weiss, MJ | 1 |
| Bauer, TW | 1 |
| Shen, F | 1 |
| Poultsides, GA | 1 |
| Marsh, JW | 1 |
| Cercek, A | 4 |
| Kemeny, N | 2 |
| Kingham, TP | 3 |
| D'Angelica, M | 3 |
| Pawlik, TM | 1 |
| Jarnagin, WR | 8 |
| Koerkamp, BG | 1 |
| Boerner, T | 1 |
| Tan, BR | 1 |
| Chou, JF | 1 |
| Gönen, M | 5 |
| Boucher, TM | 1 |
| Hauser, HF | 1 |
| Do, RKG | 1 |
| Lowery, MA | 1 |
| Harding, JJ | 1 |
| Varghese, AM | 1 |
| Reidy-Lagunes, D | 1 |
| Saltz, L | 1 |
| Schultz, N | 1 |
| D'Angelica, MI | 4 |
| DeMatteo, RP | 4 |
| Drebin, JA | 1 |
| Allen, PJ | 3 |
| Balachandran, VP | 1 |
| Lim, KH | 1 |
| Sanchez-Vega, F | 1 |
| Vachharajani, N | 1 |
| Majella Doyle, MB | 1 |
| Fields, RC | 1 |
| Hawkins, WG | 1 |
| Strasberg, SM | 1 |
| Chapman, WC | 1 |
| Diaz, LA | 1 |
| Kemeny, NE | 5 |
| Yang, X | 1 |
| Pan, J | 1 |
| Zhao, H | 1 |
| Pietge, H | 1 |
| Sánchez-Velázquez, P | 1 |
| Akhoundova, D | 1 |
| Siebenhüner, A | 1 |
| Winder, T | 1 |
| Bachmann, H | 1 |
| Nguyen-Kim, TDL | 1 |
| Breitenstein, S | 1 |
| Knuth, A | 1 |
| Petrowsky, H | 1 |
| Pestalozzi, B | 1 |
| Clavien, PA | 1 |
| Samaras, P | 1 |
| Power, D | 1 |
| Capanu, M | 1 |
| Gewirtz, A | 1 |
| Patel, D | 1 |
| Allen, P | 2 |
| Fong, Y | 5 |
| Konstantinidis, IT | 2 |
| Do, RK | 2 |
| Gultekin, DH | 2 |
| Schwartz, LH | 2 |
| Klimstra, DS | 2 |
| Kang, MH | 1 |
| Lee, WS | 1 |
| Go, SI | 1 |
| Kim, MJ | 1 |
| Lee, US | 1 |
| Choi, HJ | 1 |
| Kim, DC | 1 |
| Lee, JH | 1 |
| Kim, HG | 1 |
| Bae, KS | 1 |
| Cho, JM | 1 |
| Haviland, D | 2 |
| Shia, J | 1 |
| DeMatteo, R | 1 |
| Tse, A | 1 |
| Blumgart, LH | 1 |
| Schwartz, L | 1 |
| Yopp, A | 1 |
| Gultekin, D | 1 |
| Gewirtz, AN | 1 |
| Ben-Josef, E | 1 |
| Normolle, D | 1 |
| Ensminger, WD | 2 |
| Walker, S | 2 |
| Tatro, D | 1 |
| Ten Haken, RK | 1 |
| Knol, J | 1 |
| Dawson, LA | 1 |
| Pan, C | 1 |
| Lawrence, TS | 2 |
| Robertson, JM | 1 |
| Andrews, JC | 1 |
| Kessler, ML | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver[NCT03366155] | Phase 2 | 40 participants (Anticipated) | Interventional | 2019-06-24 | Recruiting | ||
| Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma[NCT01525069] | Phase 1 | 27 participants (Actual) | Interventional | 2012-04-03 | Terminated (stopped due to Equipment that was used in the study was discontinued) | ||
| A Phase II Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Bevacizumab (A Monoclonal Antibody to Vascular Endothelial Growth Factor-A), in Patients With Unresectable Primary Hepatic Malignancy[NCT00410956] | Phase 2 | 55 participants (Anticipated) | Interventional | 2007-05-31 | Active, not recruiting | ||
| A Phase 2 Study of Low-Dose Fractionated Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Locally Advanced Mass-Forming Intrahepatic Cholangiocarcinoma[NCT02254681] | Phase 2 | 6 participants (Actual) | Interventional | 2014-09-30 | Terminated (stopped due to lack of funding) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To determine the number of participants with Intrahepatic disease progression assessed by MRI of the abdomen with intravenous gadolinium contrast using RECIST criteria. (NCT02254681)
Timeframe: From date of first treatment until date of first documented progression or date of death from any cause, which ever comes first, assessed up to 24 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 6 |
To determine the number of participants with Intrahepatic recurrence assessed by RECIST criteria using MRI of the abdomen with intravenous gadolinium contrast. (NCT02254681)
Timeframe: From date of partial hepatectomy until date of first documented recurrence or date of death from any cause, assessed up to 24 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
Measured post-operative complications include (but not limited to) bile leak, liver failure, ascites, infection, any organ failure or insufficiency, venous thromboembolism, and mortality. (NCT02254681)
Timeframe: up to 90 days after partial hepatectomy
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
1 review available for floxuridine and Cholangiocellular Carcinoma
| Article | Year |
|---|---|
Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chola | 2022 |
6 trials available for floxuridine and Cholangiocellular Carcinoma
| Article | Year |
|---|---|
Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2020 |
Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma | 2021 |
Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile | 2014 |
Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bi | 2009 |
Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?
Topics: Aged; Alkaline Phosphatase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplasti | 2011 |
Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, In | 2005 |
7 other studies available for floxuridine and Cholangiocellular Carcinoma
| Article | Year |
|---|---|
Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cohort Studies; Female; Floxuridi | 2022 |
Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Floxuridine; Gemci | 2020 |
Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma-Reply.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Floxuridine; Gemci | 2020 |
Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile | 2014 |
Can thymidine phosphorylase be a predictive marker for gemcitabine and doxifluridine combination chemotherapy in cholangiocarcinoma?: case series.
Topics: Adult; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Cholangiocarcinoma; Deoxycy | 2014 |
Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2016 |
Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcino | 1997 |